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Long-Term Impact of
Periprocedural Bleeding
When Does It End?*
Robert J. Applegate, MD
Winston-Salem, North Carolina
The landmark observation by DeWood et al. (1) that acute
myocardial infarctions result from in situ coronary thrombosis
ushered in a new era of therapy for patients with acute coronary
syndromes. Since that time, a variety of pharmacologic treat-
ments have been developed to inhibit the coagulation cascade,
targeting almost all cellular and protein constituents of the
thrombotic process. Not surprisingly, strategies aimed at
thrombolysis, clot dissolution, and prevention of its recurrence
within the coronary tree may have similar effects in other
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vascular beds. The unintended consequences of these anti-
thrombotic therapies at noncoronary artery sites may result
in significant bleeding that in some cases, such as an
intracranial hemorrhage, may be fatal. Although bleeding as
a “side effect” of these therapies was recognized early on,
attempts to minimize bleeding was tempered by the recog-
nition that antithrombotic therapies prevented significant
recurrent ischemia and were often lifesaving. Specific exam-
ples include the use of glycoprotein IIb/IIIa inhibitors in
patients with acute coronary syndromes and percutaneous
coronary intervention (PCI) (initially balloon angioplasty)
(2) and the early intensive anticoagulant strategies to prevent
acute stent thrombosis in the first generation of bare-metal
stents (3). Thus, during the early days of management of
acute coronary syndromes, the benefits of thrombotic therapy,
particularly during PCI, outweighed the risk of bleeding.
Nonetheless, over the past 2 decades, multiple strategies
have evolved to minimize the extent and severity of bleeding
accompanying the use of antithrombotic therapies. The use
of fibrin-specific instead of nonfibrin-specific thrombolytics
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recognition of the importance of the use of lower intensity
anticoagulation with heparin in conjunction with intrave-
nous glycoprotein IIb/IIIa inhibitors for the treatment of
acute coronary syndromes (5) are just 2 examples of efforts
to lower rates of bleeding while maintaining the efficacy of
the antithrombotic therapy. During PCI, the use of lower
intensity heparin dosing in conjunction with glycoprotein
IIb/IIIa inhibitors has reduced rates of periprocedural
bleeding. Innovations in PCI technology, specifically the
development and refinement of stent therapy, have reduced
the incidence of acute stent thrombosis and the accompa-
nying need for intense periprocedural acute antithrombotic
therapies. Additionally, the introduction of bivalirudin has
provided an alternative to heparin as the anticoagulant of
choice during PCI with associated lower rates of bleeding.
Finally, a better understanding of optimal stent use has
allowed the use of dual antiplatelet therapy instead of
warfarin for the prevention of stent thrombosis. Thus, the
need for intensive anticoagulation therapy at the time of
PCI has decreased. Because of all these factors and as a
result of more predictable PCI outcomes with very low rates
of periprocedural ischemic events, the bleeding risk associ-
ated with PCI has come under close scrutiny.
There is mounting clinical evidence that periprocedural
bleeding is an independent predictor of post-procedure
adverse outcomes, including death. The adverse conse-
quences of major bleeding are most readily apparent during
the hospital course of these patients. Moreover, the reason
for the adverse nature of periprocedural bleeding is easily
understood given that the intensity of the antithrombotic
therapy occurs at this time, when there has been a transient
breach of the venous and/or arterial systems. Additionally,
however, it has been increasingly recognized that the ad-
verse consequences of periprocedural bleeding extends be-
yond the hospital, for at least as long as 6 months. Why the
impact of periprocedural bleeding should persist beyond the
hospitalization and even 30 days is not readily apparent
because the effectiveness of most of the antithrombotic
therapies would have long worn off.
The mechanisms postulated to be responsible for the
association of major bleeding and adverse outcomes can best
be considered by looking at the periprocedural period in 2
distinct phases. During the early phase, the time period
surrounding the index hospitalization for PCI and as long as
30 days thereafter, 4 mechanisms have been proposed to
explain the adverse consequences of periprocedural bleed-
ing. Frank exsanguination (e.g., retroperitoneal hemor-
rhage) is a well-recognized cause of bleeding-related mor-
tality. Also in this time period, the withdrawal of important
antithrombotic therapies can plausibly affect and lead to
ischemic consequences such as stent thrombosis, which is
often associated with significant morbidity and mortality.
Treatment of major bleeding frequently includes adminis-
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transfusions themselves are independently associated with
adverse outcomes. This could be a particular problem if
transfusions are administered by protocol (i.e., to maintain
hemoglobin 10 g/dl). Finally, the stimulation of pro-
thrombotic forces such as platelet aggregation in response to
bleeding has been put forth as potential explanation for an
increase in adverse (ischemic) events in those with major
bleeding compared with those without major bleeding.
The second phase that needs to be considered is the time
period beginning 30 days after the index procedure. During
this time period, the mechanism(s) responsible for an
adverse impact of bleeding experienced at an index hospi-
talization are not as clearly understood. There are several
questions that bear on this discussion that remain to be
clearly addressed: 1) Is the adverse association of peripro-
cedural bleeding and late morbidity and mortality similar for
the access site compared with nonaccess site of bleeding?
2) Can we demonstrate a decrease in medication use in this
later period for those who have adverse morbidity and
mortality and periprocedural bleeding? 3) Does periproce-
dural bleeding simply identify a subgroup of patients who
are at higher risk of post-procedure adverse events?
4) Finally, how long does periprocedural bleeding affect
long-term adverse outcomes?
There are published data that address some but not all of
these questions. Rao et al. (6) analyzed data from 4
randomized clinical trials evaluating the clinical efficacy of
glycoprotein IIb/IIIa inhibitors in patients with acute cor-
onary syndromes, including GUSTO IIB (Global Utiliza-
tion of Streptokinase and Tissue-Plasminogen Activator for
Occluded Coronary Arteries), PURSUIT (Platelet Glyco-
protein IIb/IIIa in Unstable Angina, Receptor Suppression
Using Integrilin Therapy), and PARAGON A and B
(Platelet IIb/IIIa Antagonism for the Reduction of Acute
coronary syndrome events in a Global Utilization Network).
In this post-hoc evaluation, they found substantially worse
in-hospital and 30-day outcomes in those with any bleed-
ing, but the relationship was most notable in those with
severe bleeding compared with those who did not have any
evidence of bleeding. Importantly, the adverse impact of
bleeding on the odds ratio of both 30-day and 6-month
mortality occurred with both procedure-related bleeds, as
well as nonprocedure-related bleeds, suggesting that the
access site itself was not solely responsible for the impact of
bleeding on mortality. Moreover, these observations were
adjusted for multiple covariates that were associated with
adverse 30-day and 6-month outcomes themselves, and
bleeding remained an independent predictor of mortality.
Eikelboom et al. (7) examined information from the OASIS
(Organization to Assess Ischemic Syndromes and the
Clopidogrel in Unstable Angina to Prevent Recurrent
Ischemic Events) Registry, OASIS II, and the CURE
(Clopidogrel in Unstable angina to prevent recurrent
Events) trials evaluating the clinical efficacy of thienopyri-dines in patients with acute coronary syndromes. They
observed a similar association between the severity of
bleeding and mortality after 30 days in these trials as did
Rao et al. (6). In this particular evaluation, major and
life-threatening but not minor bleeding was associated with
worse outcomes at 6 months. These observations persisted
despite adjustment for known baseline predictors of worse
outcomes over these time periods. Multiple other studies
have subsequently confirmed these initial important obser-
vations and have stimulated continued interest in better
understanding the relationship between initial major bleed-
ing and adverse long-term outcomes.
In this issue of the Journal, Suh et al. (8) provide
important new information on the long-term consequences
of in-hospital major bleeding from the HORIZONS-AMI
(Harmonizing Outcomes With Revascularization and
Stents in Acute Myocardial Infarction) trial. In this ran-
domized clinical trial of primary PCI for ST-segment
elevation myocardial infarction, there was a 2  2 random-
ization comparing bivalirudin with heparin plus glyco-
protein inhibitor use as well as bare-metal with paclitaxel-
eluting stent use. The overall incidence of major bleeding in
the trial during the index hospitalization was 6.5%. Similar
to previous reports, patients who experienced major bleed-
ing were more often older, female, and diabetic. This
post-hoc analysis provides 2 important pieces of informa-
tion not previously available in an evaluation of the long-
term consequences of periprocedural bleeding: landmark
analysis of mortality from index hospitalization to 3 years
and medication use from index hospitalization to 3 years.
Not unexpectedly, the hazard ratio for mortality in those
with periprocedural bleeding was the highest in the first 30
days. However, the adverse hazard ratio persisted during
each of the 2 ensuing landmark intervals, with only slight
attenuation compared with the earliest period: from 1 to 3
years, the hazard ratio of death was 3.67 (range, 2.0 to 6.52)
in those patients with major in-hospital bleeding compared
with those without this complication. This same adverse
association of periprocedural bleeding and clinical outcomes
was observed for all major adverse cardiac events, including
myocardial infarction, ischemia-driven target vascular revas-
cularization, stroke, and stent thrombosis (although not
statistically significant). Interestingly, and perhaps counter-
intuitively, aspirin use at 3 years was similar in both groups
at 95%, and thienopyridine use was similar at all time points
except at 3 years when there was a paradoxically higher use
of thienopyridines in those who had major bleeding com-
pared with those who did not have major bleeding. Also, of
note, beta-blocker and statin use was lower in those with
major bleeding compared with those who did not have
major bleeding at discharge, although there are no data
reflecting use at 3 years.
What can we learn from this post-hoc analysis of the
HORIZONS-AMI trial from Suh et al. (8)? First, these
data extend the association between in-hospital major
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appears to be independent of use of medications such as
aspirin and thienopyridines, although it is unclear what the
role of the decreased administration of beta-blocker and
statin therapy would have in these events at 3 years. These
observations provide important answers to some of the
questions about the mechanisms and duration of the adverse
association of bleeding and mortality. However, if the
adverse consequences of in-hospital major bleeding are not
related to the withdrawal of lifesaving medications (i.e., dual
antiplatelet therapy), then what is the mechanism respon-
sible for increased late mortality in these patients?
The association between major in-hospital bleeding and
increased mortality in their analysis persisted after adjust-
ment for baseline covariates. Despite this, it is concerning
that in this study, as well as multiple other studies on the
subject, major bleeding occurred more often in patients with
baseline characteristics known to be associated with worse
outcomes over this time period (e.g., older age, diabetic,
female). Is it simply that bleeding is more likely to occur in
those who are at risk of late adverse cardiac events despite
our best efforts to attempt to adjust for these confounders?
Suh et al. (8) acknowledge that their observations should
stimulate further investigation of the long-term conse-
quences of periprocedural bleeding. Until we have a clearer
understanding of the mechanisms of this association, we
will need to rely on bleeding avoidance strategies such as
gentler antithrombotic pharmacology and access techniques
that limit bleeding, to prevent the potentially morbid
cascade that seems to follow (9).Reprint requests and correspondence: Dr. Robert J. Applegate,
Section of Cardiology, Wake Forest School of Medicine, Medical
Center Boulevard, Winston-Salem, North Carolina 27157-1045.
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